Current experience with treatment of prognostically unfavourable acute myeloid leukaemias with CPX-351 at the Institute of Haematology and Blood Transfusion

Czech version

Authors: J. Valka
Authors‘ workplace: Ústav hematologie a krevní transfuze, Praha
Published in: Transfuze Hematol. dnes,30, 2024, No. 4, p. 253-259.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz20

Overview

The therapeutic agent CPX-351, Vyxeos liposomal, is a newly approved drug intended for therapy of high-risk subtypes of acute myeloid leukaemia (AML) such as AML arising from antecedent myelodysplastic syndrome or associated with previous anticancer therapy. In the Czech Republic, CPX-351 is reimbursed for patients aged 60 and over with the above-mentioned AML subtypes. The following paper describes the indication and dosage schedule of CPX-351, its mechanism of action and also briefly mentions the therapeutic results and safety profile of CPX-351 according to the product registration study. The article then focuses on current clinical experience with CPX-351 since 2022 at the UHKT Prague and analyses in detail the case reports of two patients treated at the UHKT in the last months. CPX-351 therapy represents, according to our experience so far, a relatively effective option for treating high-risk AML in which treatment with standard chemotherapy often fails.

Keywords:

acute myeloid leukaemia – myelodysplastic syndrome – CPX-351 – therapy-related AML

Sources

1. Vyxeos liposomal: EPAR –⁠ Product Information, Vyxeos liposomal (previously known as Vyxeos] https: //www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal

2. Döhner H, Wei AH, Appelbaum FR, at al. Diag -⁠ nosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140 (12): 1345–1377.

3. SÚKL, Vyxeos liposomal, ceny a úhrady. https: //prehledy.sukl.cz/prehled_leciv.html#/leciva/023 8215

4. SÚKL, Vyxeos liposomal, doprovodné texty, souhrn údajů o přípravku. https: //prehledy.sukl.cz/prehled_leciv.html#/leciva/0238215

5. Brunetti C, Anelli L, Zagaria A, Specchia G, Albano F. CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds? Expert Rev Hematol. 2017; 10 (10): 853–862.

6. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021; 8 (7): e481–e491.

7. Marconi G, Rondoni M, Zannetti BA, et al. Novel insights and therapeutic approaches in secondary AML. Front Oncol. 2024; 14 : 14 00461.

8. Uy GL, Newell LF, Lin TL, et al Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022; 6 (17): 4989–4993.

9. Guolo F, Fianchi L, Minetto P, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020; 10 (10): 96.

10. Rautenberg C, Stölzel F, Röllig C, et al. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021; 11 (10): 164.

11. Garibaldi B, Franciosa M, Pilo F, et. al. P535: Updates from italian multicenter real-life experience on CPX-351 therapy in young patients (<60 years old). HemaSphere. 2022; 6 : 434–435.

12. Othman J, Wilhelm-Benartzi C, Dillon R, et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Adv. 2023; 7 (16): 4539–4549.

13. Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022; 6 (13): 3997–4005.

14. Grenet J, Jain AG, Burkart M, et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia. Blood. 2021; 138 (Suppl 1): 32.

PROHLÁŠENÍ O KONFLIKTU ZÁJMŮ

Práce byla podpořena společností Swixx BioPharma.

Další podpora autora v uplynulých 24 měsících:

Přednášková a publikační činnost: AbbVie, Astellas, Pfizer, Servier, Swixx

Podpora účasti na odborných akcích: Pfizer, Servier, Swixx

Konzultační činnst: Astellas, Swixx

Doručeno do redakce dne: 15. 9. 2024.

Přijato po recenzi dne: 29. 10. 2024.

MUDr. Jan Válka, Ph.D.

ÚHKT Praha

U Nemocnice 1

12800 Praha 2